OccuRx launched with up to AU$6.5 M in funding

OccuRx, an Australian biopharmaceutical company developing a new class of drugs to prevent a significant health burden associated with fibrosis, was launched today with up to AU$6.5M in staged tranches of venture capital funding from a consortium including the Medical...
Breaking the science and research bottle neck

Breaking the science and research bottle neck

The following article is taken from the Australian Financial Review Magazine. Our Director, Peter Devine, talked to Tony Boyd about the potential for all of Australia’s major universities to join forces under the Uniseed umbrella. “For most economists and...